Patents Assigned to Immunex
  • Rank-ligand-induced sodium/proton antiporter polypeptides
    Publication number: 20080200389
    Abstract: This invention relates to RIPPA, a new member of the human Na+/H+ antiporter polypeptide family, methods of making such polypeptides, and to methods of using RIPPA and RIPPA-Like polypeptides and agonists or antagonists.
    Type: Application
    Filed: April 7, 2008
    Publication date: August 21, 2008
    Applicant: Immunex Corporation
    Inventors: Timothy A. Bird, Mark E. Tometsko, William C. Dougall, Bruce A. Mosley
  • Monoclonal blocking antibody to human RANKL
    Patent number: 7411050
    Abstract: Disclosed herein are kits for detecting RANKL protein or nucleic acids, the kits comprising isolated human RANKL polypeptides, RANKL nucleic acids and/or antibodies specific for RANKL.
    Type: Grant
    Filed: March 16, 2004
    Date of Patent: August 12, 2008
    Assignee: Immunex Corporation
    Inventor: Dirk M. Anderson
  • Attractin/mahogany-like polypeptides, polynucleotides, antibodies and methods of use thereof
    Patent number: 7411055
    Abstract: The present disclosure provides attractin/mahogany-like polypeptides and fragments thereof, polynucleotides encoding such polypeptides and fragments, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides or fragments, and assays and methods employing these polypeptides, antibodies, and polynucleotides.
    Type: Grant
    Filed: May 23, 2002
    Date of Patent: August 12, 2008
    Assignee: Immunex Corporation
    Inventor: Dirk M. Anderson
  • flk-1 binding protein
    Publication number: 20080188643
    Abstract: A protein designated flk-1bp binds the vascular endothelial cell surface receptor flk-1. Isolated DNA encoding flk-1bp is provided, along with expression vectors and transformed host cells useful in producing flk-1bp polypeptides. Antibodies that are immunoreactive with flk-1bp are generated using the polypeptides disclosed herein.
    Type: Application
    Filed: December 13, 2007
    Publication date: August 7, 2008
    Applicant: Immunex Corporation
    Inventor: Stewart D. Lyman
  • C-type lectin polypeptide, polynucleotide and methods of making and use thereof
    Publication number: 20080182793
    Abstract: Provided herein are polypeptide and polynucleotide sequences for a molecule having homology to the C-type lectin family of polypeptides. Also provided are methods of making and using the polypeptide and polynucleotides.
    Type: Application
    Filed: March 25, 2008
    Publication date: July 31, 2008
    Applicant: Immunex Corporation
    Inventor: Peter Robert Baum
  • Human TSLP polynucleotides
    Patent number: 7405058
    Abstract: The invention is directed to purified and isolated novel TSLP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above.
    Type: Grant
    Filed: June 13, 2006
    Date of Patent: July 29, 2008
    Assignee: Immunex Corporation
    Inventors: John E. Sims, Stewart D. Lyman, Hilary Jean McKenna, Allison P. Armstrong
  • CD40-Ligand lacking native-pattern glycosylation
    Patent number: 7405270
    Abstract: There is disclosed a polypeptide (CD40-L) and DNA sequences, vectors and transformed host cells useful in providing CD40-L polypeptides. More particularly, this invention provides isolated human and murine CD40-L polypeptides that bind to the extracellular binding region of a CD40 receptor and lack native-pattern glycosylation.
    Type: Grant
    Filed: July 19, 2002
    Date of Patent: July 29, 2008
    Assignee: Immunex Corporation
    Inventors: Richard J. Armitage, William C. Fanslow, III, Melanie K. Spriggs
  • Molecules designated LDCAM
    Patent number: 7402655
    Abstract: The invention is directed to LDCAM as a purified and isolated protein, the DNA encoding the LDCAM, host cells transfected with cDNAs encoding LDCAM, processes for preparing LDCAM polypeptides and compositions and methods for treating utilizing LDCAM polypeptides.
    Type: Grant
    Filed: February 6, 2001
    Date of Patent: July 22, 2008
    Assignee: Immunex Corporation
    Inventors: Peter Robert Baum, William Christian Fanslow, III
  • Metalloprotease-disintegrin ADAM23 (SVPH3-17)
    Patent number: 7399832
    Abstract: The invention is directed to purified and isolated novel SVPH3-13 or SVPH3-17 polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above.
    Type: Grant
    Filed: December 19, 2006
    Date of Patent: July 15, 2008
    Assignee: Immunex Corporation
    Inventor: Douglas P. Cerretti
  • Human OX2 receptors
    Publication number: 20080166813
    Abstract: Isolated receptors, nucleic acids encoding such receptors, and pharmaceutical compositions made therefrom, are disclosed. The isolated receptors can be used to regulate an immune response. The receptors are also useful in screening for inhibitors or agonists thereof.
    Type: Application
    Filed: January 30, 2007
    Publication date: July 10, 2008
    Applicant: Immunex Corporation
    Inventors: Anne-Renee Van Der Vuurst De Vries, Laurent J. Galibert
  • CD137 agonists to treat patients with IgE-mediated conditions
    Publication number: 20080166336
    Abstract: There are disclosed methods for treating conditions mediated by IgE, comprising administering a CD137 agonist to a mammal afflicted with such a condition. CD137 agonists include CD137 ligand (CD137L) and agonistic antibodies to CD137; mammals to be treated include humans. Conditions mediated by IgE include asthma, atopic dermatitis, and allergy. CD137 agonists are also useful for treating conditions characterized by delayed eosinophil apoptosis, including nasal polyps and hypereosinophilic syndrome. Patients to be treated may be afflicted with, or at risk for, one or more of these conditions.
    Type: Application
    Filed: March 27, 2007
    Publication date: July 10, 2008
    Applicant: Immunex Corporation
    Inventor: John D. Pluenneke
  • C-type lectin polypeptides
    Patent number: 7396662
    Abstract: Provided herein are polypeptide and polynucleotide sequences for a molecule having homology to the C-type lectin family of polypeptides. Also provided are methods of making and using the polypeptide and polynucleotides.
    Type: Grant
    Filed: December 19, 2002
    Date of Patent: July 8, 2008
    Assignee: Immunex Corporation
    Inventor: Peter Robert Baum
  • Inhibitory pellion nucleic acids
    Publication number: 20080161259
    Abstract: There are disclosed novel polypeptides referred to as Pellino polypeptides, as well as fragments thereof, including immunogenic peptides. DNAs encoding such polypeptides as well as methods of using such DNAs and polypeptides are also disclosed.
    Type: Application
    Filed: June 25, 2007
    Publication date: July 3, 2008
    Applicant: Immunex Corporation
    Inventors: Xiaoxia Li, Timothy A. Bird, David J. Cosman
  • Antibodies that bind TNF-alpha converting enzyme
    Publication number: 20080160571
    Abstract: A metalloprotease that converts TNF-? from the 26 kD cell form to the 17 kD form has been isolated and purified and the cDNA sequence known. In particular, the protease has a molecular weight of approximately 80 kD. The isolated and purified protease is useful for designing an inhibitor thereof, and may find use as a therapeutic agent. Assays for detecting the protease-inhibiting activity of a molecule are also an aspect of the invention.
    Type: Application
    Filed: February 21, 2007
    Publication date: July 3, 2008
    Applicant: Immunex Corporation
    Inventors: Roy A. Black, Charles Rauch, Carl J. March, Douglas P. Cerretti
  • Modified human thymic stromal lymphopoietin
    Publication number: 20080145866
    Abstract: Modified, furin resistant human TSLP polypeptides and polynucleotides encoding the modified human TSLP polypeptides are provided. Pharmaceutical compositions, B and T cell activation agents, assays and methods of use are also described.
    Type: Application
    Filed: October 30, 2007
    Publication date: June 19, 2008
    Applicant: Immunex Corporation
    Inventors: Stewart D. Lyman, Kirk P. Van Ness, Raymond J. Paxton
  • Cell culture performance with betaine
    Patent number: 7384765
    Abstract: This invention relates generally to the field of cell culture. More particularly, the invention relates to improving viability of recombinant cell cultures and the yields of secreted polypeptides therefrom by the addition of betaine to the tissue culture medium.
    Type: Grant
    Filed: May 19, 2006
    Date of Patent: June 10, 2008
    Assignee: Immunex Corporation
    Inventors: Brian D. Follstad, Anne H. Potter
  • Human IL-1 epsilon DNA and polypeptides
    Publication number: 20080108796
    Abstract: The invention is directed to purified and isolated novel human IL-1 epsilon polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, the use of such polypeptides and fragmented peptides in cellular and immune reactions and as molecular weight markers, the use of such polypeptides and fragmented peptides as controls for peptide fragmentation, and kits comprising these reagents.
    Type: Application
    Filed: June 25, 2007
    Publication date: May 8, 2008
    Applicant: Immunex Corporation
    Inventors: John Sims, Dirk Smith
  • Dendritic cell transmembrane serine protease
    Publication number: 20080102484
    Abstract: Isolated Dendritic Cell Transmembrane Serine Proteases (DCTSPs), DNAs encoding such DCTSPs, and pharmaceutical and/or diagnostic compositions made therefrom, are disclosed. The isolated DCTSPs can be used to hydrolyze peptide bonds. The DCTSPs are also useful in screening for inhibitors or agonists thereof.
    Type: Application
    Filed: December 5, 2007
    Publication date: May 1, 2008
    Applicant: Immunex Corporation
    Inventors: Dirk Anderson, G. Virca
  • Methods of using flt3-ligand in the treatment of fibrosarcoma
    Patent number: 7361330
    Abstract: Methods of treating a fibrosacroma using flt-3 ligand are disclosed, as well as methods of increasing the number of dendritic cells in a patient having a fibrosarcoma.
    Type: Grant
    Filed: September 11, 2002
    Date of Patent: April 22, 2008
    Assignee: Immunex Corporation
    Inventors: David H. Lynch, Luis Borges, Robert E. Miller, Charles R. Maliszewski
  • Novel murine and human kinases
    Publication number: 20080076141
    Abstract: The invention is directed to purified and isolated novel murine and human kinase polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above.
    Type: Application
    Filed: September 14, 2007
    Publication date: March 27, 2008
    Applicant: Immunex Corporation
    Inventors: Timothy Bird, G. Virca, Unja Martin, Dirk Anderson